Rhythm Pharmaceuticals
Yahoo Finance • 5 days ago
Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing
On February 17, 2026, Opaleye Management Inc. reported selling out its entire stake in Immunome(NASDAQ:IMNM), an estimated $37.30 million trade based on quarterly average pricing. What Happened According to its SEC filing dated February... Full story
Yahoo Finance • 5 days ago
Investment Manager Sells $5.1 Million Worth of LQDA Stock, According to Recent SEC Filing
Opaleye Management Inc. disclosed in a February 17, 2026, SEC filing that it sold 180,000 shares of Liquidia(NASDAQ:LQDA), an estimated $5.12 million trade based on quarterly average pricing. What Happened According to a SEC filing dated... Full story
Yahoo Finance • 6 days ago
Rhythm Pharmaceuticals price target lowered to $110 from $125 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $110 from $125 and keeps a Buy rating on the shares, reflecting adjustments to the firm’s long-term sales ramp expectations after Rhythm recently announced... Full story
Yahoo Finance • 10 days ago
Notable Two Hundred Day Moving Average Cross - RYTM
In trading on Friday, shares of Rhythm Pharmaceuticals Inc (Symbol: RYTM) crossed below their 200 day moving average of $93.81, changing hands as low as $91.52 per share. Rhythm Pharmaceuticals Inc shares are currently trading off about 5... Full story
Yahoo Finance • 11 days ago
Rhythm anticipates $385M–$415M in 2026 non-GAAP operating expenses as HO launch preparations accelerate
Earnings Call Insights: Rhythm Pharmaceuticals (RYTM) Q4 2025 MANAGEMENT VIEW * CEO David Meeker highlighted the continued strong performance of Rhythm’s commercial teams, noting, "The BBS opportunity continues to grow at a steady rate... Full story
Yahoo Finance • 15 days ago
Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Million
On February 17, 2026, Perceptive Advisors disclosed a significant buy of 431,432 shares of Praxis Precision Medicines(NASDAQ:PRAX), with an estimated transaction value of $80.34 million based on quarterly average pricing, according to its... Full story
Yahoo Finance • 15 days ago
Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position
On February 17, 2026, Perceptive Advisors reported a buy of Celcuity(NASDAQ:CELC), adding 203,881 shares in the fourth quarter, with an estimated transaction value of $16.76 million based on quarterly average pricing. What happened Accor... Full story
Yahoo Finance • 15 days ago
Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction
On February 17, 2026, Perceptive Advisors disclosed a buy of 978,662 shares of Apogee Therapeutics(NASDAQ:APGE), with an estimated transaction value of $61.64 million based on quarterly average pricing. What happened According to a Febru... Full story
Yahoo Finance • 15 days ago
$80 Million Arcellx Sale Follows Steep Stock Drop as Rival Drug Emerges
Perceptive Advisors disclosed a sale of 1,002,282 Arcellx(NASDAQ:ACLX) shares in a February 17, 2026, SEC filing, with the estimated transaction value at $79.96 million based on quarterly average pricing. What happened According to a SEC... Full story
Yahoo Finance • 18 days ago
Shopify, eBay upgraded: Wall Street's top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Goldman Sachs upgraded eBay (EBAY) to... Full story
Yahoo Finance • last month
Rhythm Pharmaceuticals Announces Participation in Upcoming Guggenheim Biotech Summit
BOSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today anno... Full story
Yahoo Finance • last month
This High-Flying Growth Stock Is Hiding in Plain Sight
There's a growth stock that has skyrocketed more than Google parent Alphabet(NASDAQ: GOOG)(NASDAQ: GOOGL) and Nvidia(NASDAQ: NVDA) over the last 12 months. Wall Street loves this stock, with the consensus price target reflecting a potentia... Full story
Yahoo Finance • 3 months ago
Sector Update: Health Care Stocks Advance Late Afternoon
Health care stocks rose late Thursday afternoon, with the NYSE Health Care Index up 0.9% and the Sta PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story
Yahoo Finance • 3 months ago
Sector Update: Health Care Stocks Rise Thursday Afternoon
Health care stocks rose Thursday afternoon, with the NYSE Health Care Index and the State Street Hea PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story
Yahoo Finance • 3 months ago
Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome
-- BMI and hyperphagia reductions have been observed in patients with PWS treated with setmelanotide at Month 3 (n=8) and Month 6 (n=5); 17 of 18 enrolled patients remain on therapy -- -- Promising results supportive of Phase 3, registrat... Full story
Yahoo Finance • 3 months ago
The Biotech Industry Is Healthier Than Investors Think. These Are the Stocks to Watch.
RA Capital Management’s Peter Kolchinsky says the companies that survived the industry’s 2021 rout are thriving—and looking to make deals. Continue Reading... Full story
Yahoo Finance • 3 months ago
Brinker upgraded, Coinbase downgraded: Wall Street's top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: UBS upgraded Applied Materials(AMAT) t... Full story
Yahoo Finance • 3 months ago
Rhythm Pharmaceuticals initiated with Buy at Citi on Imcivree's potential
[Wall Street New York stock exchange stock market] alexsl Rhythm Pharmaceuticals (RYTM [https://seekingalpha.com/symbol/RYTM]) initiated with a Buy/High Risk rating at Citi with a price target of $136 per share, reflecting strong convicti... Full story
Yahoo Finance • 4 months ago
Rhythm pharma down as FDA extends review period for Imcivree label expansion
[Headquarters of US Food and Drug Administration (FDA)] Grandbrothers/iStock Editorial via Getty Images Shares of Rhythm Pharmaceuticals (RYTM [https://seekingalpha.com/symbol/RYTM]) fell in the premarket on Friday after the U.S. FDA exte... Full story
Yahoo Finance • 4 months ago
Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity
-- FDA sets updated PDUFA goal date of March 20, 2026 – -- Company to hold conference today at 8:00 a.m. -- BOSTON, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceuti... Full story
